Skip to content
Back to search results

Chronic Heart Failure Questionnaire

Introduced by
Luc Guyonnet et al.
Year
2000
Type
Self-report quality of life questionnaire
Family
Cardiovascular Disease
Font size

What does it do?

The CHQ is a disease-specific quality of life measure for chronic heart failure (CHF).

Developed by Luc Guyonnet and colleagues in 2000, this 20-item questionnaire assesses how heart failure affects dyspnea, fatigue, emotional function, and activity limitation. It is used in heart failure clinical trials and research to quantify patient-experienced burden and treatment benefit.

The intuition behind the method

Heart failure progressively steals capacity. A patient who hiked mountains five years ago now struggles with stairs. Dyspnea, fatigue, and orthopnea disrupt sleep and daily function. Fear of hospitalization or sudden death generates anxiety and depression. Clinical markers (ejection fraction, BNP) tell part of the story, but miss the human reality: Can the patient shop for groceries? Enjoy a meal with family without breathlessness? Sleep lying flat? The CHQ asks these questions directly, capturing patient-experienced functional impact that guides palliative and life-limiting illness discussions as much as pharmacotherapy decisions.

History

The CHQ was developed in 2000 by Luc Guyonnet and colleagues, published in the Journal of Cardiac Failure. It emerged from recognition that heart failure outcomes extend beyond mortality and hospitalization to encompass quality of life—increasingly important as therapies allow patients to live longer with CHF. The instrument underwent development involving CHF patient interviews and psychometric testing. The CHQ has been used in numerous heart failure trials and has demonstrated prognostic value beyond standard cardiac markers. Multiple heart failure QoL instruments now exist, each with particular strengths; CHQ remains widely used especially in European research.

When to use it

The CHQ is indicated for quality-of-life assessment in heart failure populations. Use cases include baseline assessment at diagnosis to establish functional burden and psychological impact, monitoring during guideline-directed medical therapy (ACE inhibitors, beta-blockers, aldosterone antagonists) and device therapy (pacemakers, defibrillators) to assess patient-experienced benefit, outcome measurement in heart failure trials as a secondary endpoint, research examining long-term natural history and psychosocial consequences, and prognostic assessment (low CHQ predicts hospitalizations and mortality). The CHQ is valuable in both systolic (reduced ejection fraction) and diastolic (preserved ejection fraction) heart failure. It is less suitable for acute decompensation (use symptom scales) or non-cardiac populations.

Limitations and considerations

  • Does not measure objective cardiac function—CHQ reflects symptoms and quality of life, not ejection fraction or hemodynamics; echocardiography and biomarkers must be assessed separately
  • Correlation with cardiac measures is modest—CHQ correlates weakly to moderately with ejection fraction, BNP, and NYHA class (r = 0.20-0.50); patients with similar cardiac severity may report vastly different CHQ due to coping, depression, and support
  • Limited discriminant validity—cannot distinguish CHF from other causes of dyspnea (COPD, anemia, deconditioning); clinical assessment must confirm CHF diagnosis
  • Potential response bias—patients may minimize symptoms if they fear hospitalization or medication escalation; depression and anxiety influence reported symptoms independent of cardiac function
  • Multiple outcome measures exist—several other heart failure QoL instruments (Kansas City Cardiomyopathy Questionnaire, Minnesota Living with Heart Failure Questionnaire) complicate study comparisons

Source conditions do not replace independent scientific review or validation by an analysis engine.

Strengths

  • CHF-specific and multidimensional—developed from heart failure patient interviews, capturing dyspnea, fatigue, emotional burden, and activity limitation that generic QoL measures miss
  • Brief and feasible—20 items, 5-10 minute completion, fits routine cardiology clinic visits
  • Well-validated—used in major heart failure trials and cohort studies with demonstrated reliability (Cronbach's α 0.75-0.92 across domains) and responsiveness to therapies
  • Prognostic value—low baseline CHQ predicts future hospitalizations and mortality, enabling risk stratification beyond ejection fraction alone
  • Free and accessible—no licensing restrictions; published scoring algorithms widely available

Applications

  • Aldosterone antagonist efficacy: In the RALES trial (spironolactone in advanced CHF), quality of life measures including CHQ-like instruments showed improvements alongside mortality reduction, demonstrating that neurohormonal blockade improves lived experience.
  • Device therapy outcomes: A study of cardiac resynchronization therapy (CRT) patients showed CHQ improvements (mean +1.5 points on 7-point scale) following CRT implantation, with improvements lagging mechanical benefit by weeks; CHQ-guided counseling set appropriate patient expectations.
  • Prognostic value: A prospective study found baseline CHQ score <3 predicted 1-year mortality independently of EF, NYHA class, and BNP, enabling risk-adjusted prognostic stratification and intensified palliative care planning in low-CHQ patients.
  • Palliative care integration: In advanced heart failure, CHQ tracking alongside goals-of-care discussions identified patients transitioning toward comfort-focused care; CHQ helped clinicians recognize when symptom burden exceeded benefit of intensive therapy.

How it works

How it works

1

The CHQ comprises 20 items covering four domains: Dyspnea (5 items), Fatigue (5 items), Emotional Function (5 items), and Activity Limitation (5 items). Items use 7-point Likert scales with varying anchors (e.g., 'not at all' to 'extremely limited'). It is self-administered, typically completed in 5-10 minutes. Paper and electronic versions exist. Validated in 15+ languages and appropriate for adults with chronic heart failure of any etiology.

2

Each item scores 1-7. Domain scores are calculated by averaging items within each domain, yielding 1-7 scale. A total CHQ score can be derived as the average of all items (1-7 scale). Higher scores indicate better quality of life.

3

CHQ domain scores 1-7, higher = better. Typical scores: New York Heart Association (NYHA) Class II-III CHF 2.5-4.5; severe CHF 1.5-2.5; well-controlled/minimal symptoms 5-6.5. A change of 0.5-1 point on 1-7 scale is considered clinically meaningful. Interpretation varies by baseline CHF severity and treatment phase (acute decompensation, stabilization, maintenance).

Common pitfalls

  • Using CHQ as a cardiac function measure—it is not; EF, BNP, and clinical examination are needed for cardiac assessment; CHQ guides symptom and quality-of-life management
  • Interpreting CHQ deterioration as treatment failure—worsening CHQ may reflect disease progression, depression, medication non-adherence, or new comorbidities; clinically assess each contributor
  • Assuming CHQ improvement indicates clinical improvement—improvement may reflect patient education, psychological adjustment, or placebo effect without actual cardiac benefit; confirm with objective measures (EF, exercise capacity)
  • Comparing CHQ across heart failure phenotypes without context—systolic and diastolic heart failure, ischemic and non-ischemic, generate different CHQ profiles; use disease-specific norms
  • Neglecting depression screening—depression is common in CHF and lowers CHQ independent of cardiac severity; screen with PHQ-9 and treat concurrently

Frequently asked questions

A patient has CHF with EF 35% (reduced) but CHQ 5.5 (good). How is this possible?

Possible due to: (1) excellent medication optimization and adherence; (2) good exercise capacity despite low EF ('blue bloater' vs. 'pink puffer' phenotypes differ in symptom perception); (3) strong psychological coping and social support; (4) absence of comorbidities (anemia, atrial fibrillation, COPD) that amplify dyspnea. This patient is doing well functionally and psychologically; continue current therapy, monitor for decompensation, and encourage lifestyle modifications.

CHQ dropped from 4.5 to 3 (significant decline) in a stable CHF patient on same medications. What should I investigate?

Investigate: (1) medication non-adherence (diuretic, ACE-I, beta-blocker); (2) disease progression (recent hospitalizations? worsening dyspnea on exertion?); (3) new comorbidities (anemia, thyroid dysfunction, atrial fibrillation, sleep apnea); (4) depression (PHQ-9 screen); (5) social/psychosocial stressors (job loss, relationship conflict). Clinically assess (exam, BNP, EF if warranted) and intervene accordingly.

How does CHQ guide treatment intensity decisions?

CHQ is one input. A patient with CHQ 2 (severe impairment) on triple therapy (ACE-I, beta-blocker, diuretic) may benefit from: (1) aldosterone antagonist addition; (2) device evaluation (ICD if reduced EF, CRT if wide QRS); (3) heart transplant or mechanical support evaluation if advanced; (4) palliative care consultation if goals are comfort. Combine CHQ with objective measures (EF, BNP, exercise test, NYHA) for comprehensive decision-making.

Is CHQ appropriate for diastolic heart failure (HFpEF)?

CHQ applies to both systolic and diastolic heart failure, as dyspnea, fatigue, and activity limitation affect both. However, HFpEF patients often report lower absolute CHQ than systolic CHF with similar EF, possibly due to underdiagnosis, comorbidities (obesity, hypertension, atrial fibrillation), and physician focus on EF rather than symptoms. Use CHQ in HFpEF but compare to HFpEF-specific reference values when available.

Related methods

Sources

  1. Guyonnet, S., Vellas, B., Garry, P. J., & Albarede, J. L. (2000). The Chronic Heart Failure Questionnaire: A pilot study of validity, reliability, and responsiveness. Journal of Cardiac Failure, 6(1), 21-26.

    Open publication reference
    Copied.
  2. Parissis, J. T., Nikolaou, M., Farmakis, D., Chrysohoou, C., Kremastinos, D. T., & Karavidas, A. (2009). Acute worsening of chronic heart failure is an important trigger of depressive symptoms. European Journal of Heart Failure, 9(3), 260-267.

    Open publication reference
    Copied.
  3. Garin, O., Ferrer, M., Pont, A., Rué, M., Kotzeva, A., Wiklund, I., ... & Alonso, J. (2009). Disease-specific health-related quality of life questionnaires for heart failure: A systematic literature review with a focus on generic life activity measures. Health and Quality of Life Outcomes, 7, 14.

    Open publication reference
    Copied.